Overcoming Patient Barriers to Initiating Insulin Therapy in Type 2 Diabetes Mellitus

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Data from clinical trials underscore the fact that loss of β-cell function and insulin hyposecretion are progressive in type 2 diabetes. To achieve adequate glycemic control, most patients will eventually require insulin. Addition of insulin to sulfonylurea therapy, when maximal sulfonylurea does not adequately maintain fasting plasma glucose levels at <108 mg/dL, has been found to be more effective than initiating insulin therapy after oral agents have failed to maintain glycemic control. Nonetheless, both patients and providers are reluctant to begin insulin therapy. Research has shown that providers often delay modification of the diabetes treatment regimen because they believe their patients would be concerned about starting insulin therapy. In addition, they are concerned about patient nonadherence to nonpharmacologic and pharmacologic therapy. There are multiple reasons for patient nonadherence to insulin therapy; however, patients must be made to understand, early in the course of the disease, the progressive nature of type 2 diabetes and that exogenous insulin is an additional therapeutic option to help them achieve and maintain adequate glycemic control.

Original languageEnglish
Pages (from-to)33-43
Number of pages11
JournalClinical Cornerstone
Volume8
Issue number2
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Type 2 Diabetes Mellitus
Insulin
Therapeutics
Patient Compliance
Fasting
Clinical Trials
Glucose
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Overcoming Patient Barriers to Initiating Insulin Therapy in Type 2 Diabetes Mellitus. / Marrero, David.

In: Clinical Cornerstone, Vol. 8, No. 2, 2007, p. 33-43.

Research output: Contribution to journalArticle

@article{cf1482f8d550442aa266260b11c40182,
title = "Overcoming Patient Barriers to Initiating Insulin Therapy in Type 2 Diabetes Mellitus",
abstract = "Data from clinical trials underscore the fact that loss of β-cell function and insulin hyposecretion are progressive in type 2 diabetes. To achieve adequate glycemic control, most patients will eventually require insulin. Addition of insulin to sulfonylurea therapy, when maximal sulfonylurea does not adequately maintain fasting plasma glucose levels at <108 mg/dL, has been found to be more effective than initiating insulin therapy after oral agents have failed to maintain glycemic control. Nonetheless, both patients and providers are reluctant to begin insulin therapy. Research has shown that providers often delay modification of the diabetes treatment regimen because they believe their patients would be concerned about starting insulin therapy. In addition, they are concerned about patient nonadherence to nonpharmacologic and pharmacologic therapy. There are multiple reasons for patient nonadherence to insulin therapy; however, patients must be made to understand, early in the course of the disease, the progressive nature of type 2 diabetes and that exogenous insulin is an additional therapeutic option to help them achieve and maintain adequate glycemic control.",
author = "David Marrero",
year = "2007",
doi = "10.1016/S1098-3597(09)60006-5",
language = "English",
volume = "8",
pages = "33--43",
journal = "Clinical Cornerstone",
issn = "1098-3597",
publisher = "Excerpta Medica",
number = "2",

}

TY - JOUR

T1 - Overcoming Patient Barriers to Initiating Insulin Therapy in Type 2 Diabetes Mellitus

AU - Marrero, David

PY - 2007

Y1 - 2007

N2 - Data from clinical trials underscore the fact that loss of β-cell function and insulin hyposecretion are progressive in type 2 diabetes. To achieve adequate glycemic control, most patients will eventually require insulin. Addition of insulin to sulfonylurea therapy, when maximal sulfonylurea does not adequately maintain fasting plasma glucose levels at <108 mg/dL, has been found to be more effective than initiating insulin therapy after oral agents have failed to maintain glycemic control. Nonetheless, both patients and providers are reluctant to begin insulin therapy. Research has shown that providers often delay modification of the diabetes treatment regimen because they believe their patients would be concerned about starting insulin therapy. In addition, they are concerned about patient nonadherence to nonpharmacologic and pharmacologic therapy. There are multiple reasons for patient nonadherence to insulin therapy; however, patients must be made to understand, early in the course of the disease, the progressive nature of type 2 diabetes and that exogenous insulin is an additional therapeutic option to help them achieve and maintain adequate glycemic control.

AB - Data from clinical trials underscore the fact that loss of β-cell function and insulin hyposecretion are progressive in type 2 diabetes. To achieve adequate glycemic control, most patients will eventually require insulin. Addition of insulin to sulfonylurea therapy, when maximal sulfonylurea does not adequately maintain fasting plasma glucose levels at <108 mg/dL, has been found to be more effective than initiating insulin therapy after oral agents have failed to maintain glycemic control. Nonetheless, both patients and providers are reluctant to begin insulin therapy. Research has shown that providers often delay modification of the diabetes treatment regimen because they believe their patients would be concerned about starting insulin therapy. In addition, they are concerned about patient nonadherence to nonpharmacologic and pharmacologic therapy. There are multiple reasons for patient nonadherence to insulin therapy; however, patients must be made to understand, early in the course of the disease, the progressive nature of type 2 diabetes and that exogenous insulin is an additional therapeutic option to help them achieve and maintain adequate glycemic control.

UR - http://www.scopus.com/inward/record.url?scp=41949118743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949118743&partnerID=8YFLogxK

U2 - 10.1016/S1098-3597(09)60006-5

DO - 10.1016/S1098-3597(09)60006-5

M3 - Article

C2 - 18357954

AN - SCOPUS:41949118743

VL - 8

SP - 33

EP - 43

JO - Clinical Cornerstone

JF - Clinical Cornerstone

SN - 1098-3597

IS - 2

ER -